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AUTHOR'S SUMMARY
We investigated the association between body mass index and clinical outcomes of peripheral 
artery disease (PAD) after endovascular therapy (EVT). A total of 2914 PAD patients 
undergoing EVT were participated according to body mass index groups. Underweight was 
significantly associated with increased risk of major adverse cardiovascular events (MACE) 
(adjusted hazard ratio [HR], 1.540; 95% confidence interval [CI], 1.091–2.173) and major 
adverse limb events (MALE) (adjusted HR, 1.523; 95% CI, 1.066–2.177) compared with 
normal weight. Plus, overweight was associated with lower risk of MACE and not with MALE. 
However, obesity showed no significant association with MACE or MALE. 
ABSTRACT
Background and Objectives: Few studies have investigated the obesity paradox in clinical 
outcomes of peripheral artery disease (PAD). We investigated the association between body mass 
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index (BMI) and clinical outcomes in PAD patients undergoing endovascular therapy (EVT).
Methods: Patients (n=2,914) from the retrospective Korean Vascular Intervention Society 
Endovascular Therapy in Lower Limb Artery Disease registry were categorized according to 
BMI: underweight (<18.5 kg/m2, n=204), normal weight (18.5–25 kg/m2, n=1,818), overweight 
(25–30 kg/m2, n=766), or obese (≥30 kg/m2, n=126). Groups were compared for major adverse 
cardiovascular events (MACE) and major adverse limb events (MALE).
Results: The underweight and obese groups were older and had more frequent critical 
limb ischemia and infrapopliteal artery disease than the normal or overweight groups (all 
p<0.001). Hypertension and diabetes were more frequent and current smoking was less 
frequent in the overweight and obese groups than the underweight or normal weight groups 
(all p <0.001). The underweight group showed the higher rates of MACE and MALE at 3 years 
(17.2%, 15.7%) compared with the normal weight (10.8%, 11.7%), overweight (8.4%, 10.7%), 
or obese groups (8.7%, 14.3%) (log-rank p<0.001, p=0.015). In contrast, the risk of MACE 
was lower in the overweight than the normal weight group (adjusted hazard ratio, 0.706; 95% 
CI, 0.537–0.928).
Conclusions: In PAD patients undergoing EVT, underweight was an independent predictor for 
MACE and MALE, whereas MACE risk was lower for overweight than normal weight patients.
Trial Registration: ClinicalTrials.gov Identifier: NCT02748226
Keywords: Peripheral artery disease; Body mass index; Endovascular procedure; Prognosis
INTRODUCTION
As global life expectancy rises and the diabetic population grows, the prevalence of 
peripheral artery disease (PAD) is also increasing. PAD is mainly caused by atherosclerosis 
and is associated with increased risk of cardiovascular death and morbidity.1) Furthermore, 
progressive atherosclerotic changes in PAD may lead to ischemic injury and may even 
require limb amputation.2) Although obesity is generally considered a risk factor for 
diabetes, hypertension, dyslipidemia, and coronary artery disease, clinical trials have 
demonstrated that overweight or obesity are associated with better prognosis in patients 
with cardiovascular disease (CVD).3) In contrast, death rates were shown to be higher in 
underweight patients with or without CVD.4) The pathophysiology behind this phenomenon 
remains poorly understood. This so-called obesity paradox has also been described in 
PAD patients.5) However, few studies have investigated the association between body mass 
index (BMI) and clinical outcomes of PAD.6)7) Thus, the present study aimed to investigate 




The study was conducted in accordance with the Declaration of Helsinki as revised in 
2013 and approved by the Institutional Review Board of each participating hospital. The 
Institutional Review Boards of the participating hospitals waived the requirement for 
informed consent because of the retrospective nature of the study.
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Study population
This study analyzed the retrospective cohort data of the Korean Vascular Intervention Society 
Endovascular Therapy in Lower Limb Artery Diseases (K-VIS ELLA) registry, a multicenter, 
observational retrospective and prospective cohort (ClinicalTrials.gov NCT02748226). The 
retrospective analysis included 3,073 patients with 3,972 target limbs who received EVT 
between January 2006 and July 2015 in 31 hospitals in Korea.8) After exclusion of patients 
without BMI information (n=159), 2914 patients were included in the present analysis. The 
distribution of BMI in the total population is presented in Supplementary Figure 1. Patients 
were categorized into four groups according to underweight, BMI <18.5 kg/m2, n=204; 
normal weight, BMI 18.5 to 24.9 kg/m2, n=1818; overweight, BMI 25 to 29.9 kg/m2, n=766, or 
obese, BMI ≥30 kg/m2, n=126.9)
Data of baseline characteristics, lesion characteristics, and clinical outcomes were collected 
by review of electronic medical records and angiography.
Clinical outcomes and definitions
The primary outcomes were major adverse cardiovascular event (MACE) and major adverse 
limb event (MALE). MACE was defined as a composite of all-cause deaths, myocardial 
infarctions, and strokes. MALE was defined as a composite of repeat revascularizations and 
major amputations. The secondary outcomes were cardiac death and individual components 
of the two primary outcomes. All-cause death was defined as any death, whether cardiac or 
non-cardiac in origin. Cardiac death was considered any death without definite non-cardiac 
cause. Myocardial infarction (MI) was defined as an event with a rise and/or fall of cardiac 
troponin values with at least one value above the 99th percentile upper reference limit in 
presence of symptoms of myocardial ischemia, new ischemic electrocardiogram changes, 
development of pathological Q waves, imaging evidence of new loss of viable myocardium 
or new regional wall motion abnormality in a pattern consistent with an ischemic etiology, 
or identification of a coronary thrombus by angiography.10) Stroke was defined as any 
occurrence of a neurological deficit confirmed by a neurologist, and with related abnormal 
findings in brain imaging studies.11) Repeat revascularization was defined as repeated open or 
endovascular interventions in the target limb. Major amputation was defined as above-the-
ankle amputation of the index limb.
Statistical analyses
Continuous variables are expressed as mean ± standard deviation and were compared 
using analysis of variance. Categorical variables are reported as frequencies (percentage) 
and were compared using the Chi-squared or Fisher's exact tests. Event-free survival was 
analyzed using Kaplan-Meier survival curves and compared among different groups using 
the log-rank test. Univariable and multivariable Cox proportional hazard regression analysis 
was performed to calculate the hazard ratio (HR), and to identify independent predictors 
for clinical outcomes. Variables achieving p<0.15 in the univariable analysis with age, sex, 
or diabetes, congestive heart failure were entered in the multivariable analysis. HRs are 
presented as unadjusted and multivariable-adjusted. All analyses were performed using IBM 
SPSS 25.0 for Windows (SPSS Inc., Chicago, IL, USA) and R statistical software version 3.5.2 
(R Foundation for Statistical Computing, Vienna, Austria). A value of p<0.05 was considered 
statistically significant.
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RESULTS
Baseline clinical characteristics
Baseline characteristics of the study population according to BMI groups are summarized 
in Table 1. The obese and underweight groups were older than the normal weight and 
overweight groups. Male was the dominant gender, with presence above 80% in all BMI 
groups except the obese group (47.6%). Presence of hypertension and diabetes were more 
frequent, and current smoking was less frequent, in the overweight and obese groups than 
in the underweight and normal weight groups. Coronary artery disease also showed a trend 
toward increased prevalence at higher BMI (p=0.058). Congestive heart failure (CHF) and 
critical limb ischemia (CLI) were present more frequently in the underweight and obese 
groups than in the normal weight and overweight groups. Similarly, multilevel vessel disease 
was more frequently observed in the underweight and the obese groups than in the normal 
weight and overweight groups. Infrapopliteal artery disease also occurred more frequently in 
the underweight and the obese groups than in the normal weight and overweight groups.
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Table 1. Baseline characteristics of subjects according to BMI category
Characteristics
BMI category
Underweight (n=204) Normal (n=1,818) Overweight (n=766) Obese (n=126) p value
Age (years) 69.8±10.7 68.2±9.2 67.7±9.2 72.3±9.4 <0.001
Male 168 (82.4) 1,547 (85.1) 626 (85.1) 60 (47.6) <0.001
Hypertension 121 (59.3) 1,324 (72.8) 597 (77.9) 106 (84.1) <0.001
Diabetes 87 (42.6) 1,031 (56.7) 486 (63.4) 94 (74.6) <0.001
Dyslipidemia 66 (32.4) 729 (40.1) 320 (41.8) 37 (29.4) 0.008
Coronary artery disease 103 (50.5) 993 (54.6) 448 (58.5) 78 (61.9) 0.058
Myocardial infarction 20 (9.8) 184 (10.1) 96 (12.5) 11 (8.7) 0.259
CKD 38 (18.6) 372 (20.5) 143 (18.7) 23 (18.3) 0.686
ESRD 25 (12.3) 205 (11.3) 76 (9.9) 10 (7.9) 0.467
CHF 21 (10.3) 107 (5.9) 38 (5.0) 10 (7.9) 0.030
Stroke 36 (17.6) 251 (13.8) 129 (16.8) 16 (12.7) 0.127
History of smoking 126 (64.6) 1,112 (65.0) 451 (62.1) 47 (39.8) <0.001
Previous EVT 18 (8.8) 204 (11.2) 66 (8.6) 8 (6.3) 0.084
Previous bypass surgery 5 (2.5) 60 (3.3) 20 (2.6) 1 (0.8) 0.346
Previous amputation 21 (10.3) 108 (5.9) 42 (5.5) 7 (5.6) 0.075
Pre-EVT ABI 0.58±0.27 0.64±0.25 0.66±0.26 0.62±0.32 0.030
Clinical manifestation <0.001
CLI 93 (45.6) 586 (32.2) 262 (34.2) 59 (46.8)
Claudication 111 (54.4) 1,232 (67.8) 504 (65.8) 67 (53.2)
Involved vessel
Aortoiliac 93 (45.6) 907 (49.9) 374 (48.8) 51 (40.5) 0.159
Femoropopliteal 123 (60.3) 1,060 (58.3) 402 (52.5) 70 (55.6) 0.035
Infrapopliteal 86 (42.2) 635 (34.9) 315 (41.1) 77 (61.1) <0.001
Multilevel disease 90 (44.1) 698 (38.4) 282 (36.8) 61 (48.4) 0.033
Medication
Aspirin 174 (86.6) 1,509 (85.3) 665 (89.4) 120 (96.8) <0.001
Clopidogrel 168 (83.6) 1,484 (83.9) 627 (84.3) 111 (89.5) 0.419
Cilostazol 79 (39.3) 607 (34.3) 281 (37.8) 57 (46.0) 0.024
Warfarin 11 (5.5) 142 (8.0) 57 (7.7) 3 (2.4) 0.088
Statin 130 (64.7) 1,243 (70.3) 558 (75.0) 99 (79.8) 0.002
Beta-blocker 65 (32.3) 634 (35.8) 265 (35.6) 42 (33.9) 0.774
RAS blockade 74 (36.8) 788 (44.5) 380 (51.1) 65 (52.4) <0.001
CCB 63 (31.3) 591 (33.4) 278 (37.4) 50 (40.3) 0.095
Except as noted, values represent numbers of patients, with percentages given in parentheses.
ABI = ankle-brachial index; BMI = body mass index; CCB = calcium channel blocker; CHF = congestive heart failure; CKD = chronic kidney disease; CLI = critical 
limb ischemia; ESRD = end-stage renal disease; EVT = endovascular therapy; PCI = percutaneous coronary intervention; RAS = renin-angiotensin system.
Risk of procedure complications and in-hospital adverse events according to 
body mass index categories
Incidences of procedure complications and in-hospital adverse events are presented in Table 2.  
There was no difference in the procedure-related complications. However, obese group 
showed more access site complications (p=0.001). However, in-hospital events did not differ 
significantly across the BMI categories (p=0.638).
Mid-term clinical outcomes according to body mass index categories
A total of 344 (10.4%) MACE events and 371 (12.7%) MALE events occurred during the 
follow-up period (median 720 days; interquartile range 351–1,046 days). Clinical outcomes 
according to the BMI groups, including MACE, MALE, all-cause death, and target lesion 
revascularizations (TLR), are presented in Figure 1. Accumulated events of cardiovascular 
death, MI, stroke, and major amputation are shown in Supplementary Figure 2.
The underweight group showed the highest rates of MACE (17.2%) and all-cause death at 3 
years (16.2%) compared with the normal weight (10.8% and 8.6%), overweight (8.4% and 
6.5%), and obese groups (8.7% and 7.1%) (Figure 1A and B). The underweight group also 
showed the highest rates of MALE (15.7%) and TLR (13.2%) at 3 years, compared with the 
normal weight (11.7% and 10.5%), overweight (10.7% and 9.4%), and obese groups (14.3% 
and 11.9%) (Figure 1C and D).
The unadjusted and adjusted HRs for MACE and MALE according to BMI categories are 
presented in Table 3. The underweight group exhibited significantly higher risk of MACE 
(adjusted HR, 1.540; 95% CI, 1.091–2.173) and MALE (adjusted HR, 1.523; 95% CI, 1.066–
2.177) compared with the normal weight group, after adjustment for confounding factors. 
Furthermore, the underweight group also showed significantly increased risk of all-cause 
death (adjusted HR, 1.793; 95% CI, 1.252–2.568), cardiac death (adjusted HR, 1.769; 95% 
CI, 1.043–2.999), and repeat revascularization (adjusted HR, 1.476; 95% CI, 1.005–2.166) 
compared with the normal weight group.
In contrast, the overweight group showed significantly decreased risks of MACE (adjusted 
HR, 0.706; 95% CI, 0.537–0.928), all-cause death (adjusted HR, 0.692; 95% CI, 0.508–
0.942), and cardiac death (adjusted HR, 0.594; 95% CI, 0.365–0.965) compared with the 
normal weight group. However, overweight was not significantly associated with the risk of 
MALE. The obese group showed no association with either MACE or MALE.
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Table 2. Incidences of procedural complications and in-hospital adverse events according to body mass index category
Underweight (n=204) Normal (n=1,818) Overweight (n=766) Obese (n=126) p value
Procedural complications
Any complication 7 (3.4) 80 (4.4) 38 (5.0) 11 (8.7) 0.121
Bleeding 4 (2.0) 54 (3.0) 23 (3.0) 8 (6.4) 0.139
Access site complication 3 (1.5) 41 (2.3) 23 (3.0) 10 (7.9) 0.001
Distal embolism 1 (0.5) 12 (0.7) 7 (0.9) 0 0.663
In-hospital adverse events
All in-hospital events 4 (2.0) 49 (2.7) 15 (2.0) 4 (3.2) 0.638
In-hospital mortality 4 (2.0) 39 (2.2) 10 (1.3) 3 (2.4) 0.538
Myocardial infarction 1 (0.5) 3 (0.2) 1 (0.1) 0 0.681
Stroke 1 (0.5) 3 (0.2) 0 0 0.364
Unexpected amputation 0 7 (0.4) 4 (0.5) 1 (0.8) 0.671
Values represent numbers of patients, with percentage given in parentheses.
In restricted cubic spline regression analysis, negative non-linear association was observed 
between continuous BMI and the risks of MACE and MALE (Figure 2A and B).
Independent predictors of primary outcomes
Independent predictors of MACE and MALE are shown in Table 4. Underweight (HR, 1.539; 
95% CI, 1.079–2.193) was identified in multivariable analysis as a significant predictor for 
MACE, along with age, end-stage renal disease, chronic heart failure, previous history of MI, 
stroke, peripheral bypass surgery, and CLI. The underweight category was also found to be 
a significant predictor of MALE (HR, 1.510; 95% CI, 1.056–2.160), along with male gender, 
end-stage renal disease, previous stroke, EVT procedure, and CLI.
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Figure 1. Kaplan-Meier curves of major clinical outcomes according to body mass index categories. (A) MACEs; (B) all-cause death; (C) MALEs; (D) TLR. 
MACE = major adverse cardiac events; MALE = major adverse limb events; TLR = target lesion revascularization.
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Overweight (n=766) Obese (n=126)
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
MACE
Unadjusted 1.84 (1.32–2.58) <0.001 1 0.71 (0.54–0.93) 0.014 0.88 (0.49–1.57) 0.652
Adjusted* 1.54 (1.09–2.17) 0.014 1 0.71 (0.54–0.93) 0.013 0.73 (0.40–1.32) 0.296
MALE
Unadjusted 1.62 (1.14–2.30) 0.007 1 0.89 (0.70–1.14) 0.363 1.30 (0.81–2.07) 0.280
Adjusted† 1.52 (1.07–2.18) 0.021 1 0.88 (0.69–1.13) 0.320 1.13 (0.69–1.83) 0.636
All-cause death
Unadjusted 2.17 (1.53–3.09) <0.001 1 0.69 (0.51–0.94) 0.019 0.80 (0.41–1.57) 0.519
Adjusted* 1.79 (1.25–2.57) 0.001 1 0.69 (0.51–0.94) 0.019 0.65 (0.33–1.29) 0.215
Cardiac death
Unadjusted 2.41 (1.45–4.03) 0.001 1 0.62 (0.39–1.01) 0.055 0.42 (0.10–1.73) 0.231
Adjusted* 1.77 (1.04–3.00) 0.034 1 0.60 (0.37–0.97) 0.036 0.31 (0.07–1.27) 0.104
MI
Unadjusted 1.58 (0.47–5.33) 0.460 1 1.41 (0.69–2.88) 0.347 0.82 (0.11–6.12) 0.845
Adjusted* 1.42 (0.41–4.87) 0.579 1 1.26 (0.61–2.60) 0.533 0.64 (0.08–5.01) 0.673
Stroke
Unadjusted 1.29 (0.51–3.28) 0.587 1 0.61 (0.32–1.19) 0.148 0.84 (0.20–3.50) 0.814
Adjusted* 1.10 (0.43–2.82) 0.851 1 0.61 (0.31–1.18) 0.141 0.74 (0.17–3.19) 0.686
Major amputation
Unadjusted 2.32 (0.95–5.67) 0.065 1 1.27 (0.65–2.50) 0.487 1.76 (0.53–5.86) 0.354
Adjusted† 1.78 (0.72–4.40) 0.213 1 1.21 (0.61–2.41) 0.587 1.25 (0.35–4.53) 0.734
TLR
Unadjusted 1.52 (1.04–2.22) 0.029 1 0.87 (0.67–1.13) 0.301 1.21 (0.73–2.01) 0.467
Adjusted† 1.48 (1.01–2.17) 0.047 1 0.86 (0.66–1.12) 0.272 1.10 (0.65–1.87) 0.727
BMI = body mass index; CI = confidence interval; HR = hazard ratio; MACE = major adverse cardiovascular events; MALE = major adverse limb events; MI = 
myocardial infarction; TLR = target lesion revascularization.
MACE includes all-cause death, myocardial infarction, and stroke.
MALE includes major amputation and peripheral revascularization for ischemia.
*Adjusted for age, sex, diabetes, end-stage renal disease, chronic heart failure, previous stroke, previous myocardial infarction, previous bypass surgery, and 
critical limb ischemia.






























Figure 2. Negative non-linear association between BMI and risk of MACE (A) or MALE (B). The dotted lines indicate 95% confidence interval. 
BMI = body mass index; HR = hazard ratio; MACE = major adverse cardiac events; MALE = major adverse limb events.
DISCUSSION
The main findings of our study are as follows: 1) In PAD patients, underweight was 
significantly associated with increased risk of MACE and MALE compared with normal 
weight. In addition, underweight also showed significantly increased risk for all-cause 
death, cardiac death, and TLR compared with normal weight. 2) Overweight was associated 
with lower risk of MACE, all-cause death, and cardiac death compared with normal weight. 
However, overweight showed no impact on MALE. 3) Obesity showed no significant 
association with MACE or MALE. 4) Underweight was identified as an independent predictor 
for MACE as well as for MALE. 5) There was a negative non-linear association between 
continuous BMI and the risk of MACE and MALE.
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Table 4. Predictors for MACE and MALE
Variables
Univariable Multivariable
HR 95% CI p value HR 95% CI p value
MACE predictors
Age 1.04 1.03–1.06 <0.001 1.05 1.04–1.07 <0.001
Male 0.79 0.60–1.02 0.073 1.06 1.08–2.19 0.732
BMI categories 0.016 0.001
Underweight 1.84 1.32–2.58 <0.001 1.54 1.08–2.19 0.017
Normal weight 1.00 1.00
Overweight 0.71 0.54–0.93 0.014 0.70 0.53–0.93 0.013
Obese 0.88 0.490–1.57 0.652 0.72 0.39–1.31 0.276
Hypertension 1.37 1.06–1.79 0.018 1.18 0.89–1.55 0.250
DM 1.25 1.01–1.55 0.045 1.02 0.80–1.31 0.878
Dyslipidemia 0.82 0.66–1.02 0.072 0.86 0.68–1.09 0.203
ESRD 3.47 2.69–4.47 <0.001 3.36 2.49–4.52 <0.001
CHF 2.47 1.79–3.41 <0.001 2.32 1.67–3.23 <0.001
MI 1.43 1.06–1.92 0.018 1.58 1.16–2.15 0.004
Stroke 1.64 1.27–2.12 <0.001 1.46 1.12–1.91 0.005
Amputation 1.47 0.99–2.18 0.054 0.90 0.58–1.40 0.649
Peripheral bypass surgery 1.64 1.00–2.67 0.048 1.83 1.11–3.00 0.018
CLI 1.82 1.47–2.27 <0.001 1.38 1.07–1.77 0.014
History of smoking 0.61 0.49–0.77 <0.001 0.81 0.62–1.04 0.094
MALE predictors
Age 1.00 0.99–1.01 0.825 1.00 0.99–1.01 0.711
Male 0.68 0.54–0.87 0.002 0.73 0.54–0.98 0.034
BMI category 0.016 0.033
Underweight 1.62 1.14–2.30 0.007 1.51 1.06–2.16 0.024
Normal weight 1.00
Overweight 0.89 0.70–1.14 0.363 0.83 0.64–1.07 0.141
Obese 1.30 0.81–2.07 0.280 1.01 0.61–1.69 0.965
DM 1.42 1.15–1.75 0.001 1.11 0.87–1.40 0.410
ESRD 1.84 1.45–2.33 <0.001 2.06 1.54–2.77 <0.001
CHF 1.22 0.81–1.85 0.346 1.20 0.78–1.84 0.407
CAD 0.86 0.70–1.05 0.133 0.88 0.71–1.08 0.225
Stroke 1.38 1.06–1.79 0.016 1.37 1.05–1.79 0.021
Amputation 2.06 1.47–2.89 <0.001 1.19 0.83–1.72 0.350
Previous EVT 1.89 1.45–2.48 <0.001 1.84 1.39–2.43 <0.001
CLI 2.13 1.73–2.62 <0.001 1.70 1.34–2.16 <0.001
History of smoking 0.76 0.62–0.95 0.014 1.11 0.86–1.43 0.431
Only variables with p<0.15 in the univariable analysis are shown in this table. Variables with p<0.15 in the univariable analysis were included in the multivariable model.
MACE includes all-cause death, myocardial infarction and stroke.
MALE includes major amputation and peripheral revascularization for ischemia.
BMI = body mass index; CAD = coronary artery disease; CHF = chronic heart failure; CI = confidence interval; CLI = chronic limb ischemia; DM = diabetes mellitus; 
ESRD = end-stage renal disease; EVT = endovascular therapy; HR = hazard ratio; MACE = major adverse cardiovascular events; MALE = major adverse limb events.
Our study findings are consistent with those of previous studies investigating the influence 
of BMI on prognosis for patients with PAD. Golledge et al.5) reported an inverse association 
between BMI and the risk of death in patients with PAD. They found that underweight was 
associated with approximately two-fold higher mortality risk, while overweight and obesity 
were associated with about 30–40% decrease in mortality risk.
In another retrospective cohort study of CLI patients undergoing EVT for infrapopliteal artery 
lesions, the underweight group showed a higher death rate, whereas overweight and obese 
groups showed lower death rates than the normal weight group.12) However, the weight status 
had no impact on MALE in that analysis.
A recent analysis using the National Inpatient Sample database showed that patients in the 
low BMI group were more likely to experience in-hospital death, MACE, open bypass surgery, 
or infection compared with the normal BMI group.13) However, procedural complications, 
such as vascular complication or major bleeding, did not differ between the patient groups. 
In contrast, in the present study, we found no significant trend in in-hospital adverse 
events according to body weight status, possibly due to the small number of these events. 
However, incidences of access site complications were higher with increasing BMI. This 
may be explained by the greater depth of the access vessel, which may make it more difficult 
to precisely puncture the target vessel, and to apply effective hemostasis after the removal 
of vascular sheath.14) Previous studies investigating the relationship between BMI and 
procedural complications have reported conflicting results, possibly due to differences in 
study populations and procedures.15)16)
In the present study, underweight, end-stage renal disease, and CLI were identified as 
common independent predictors for MACE as well as for MALE. These predictors were also 
found in previous studies evaluating prognostic factors of PAD. Murata et al.12) reported that 
underweight and chronic renal failure were independent predictors for death in patients 
with CLI after EVT for isolated infra-popliteal artery lesion. Kumakura et al.17) revealed that 
low BMI, estimate glomerular filtration rate, and CLI were significant risk factors for both 
all-cause and cardiovascular death in PAD. However, to the best of our knowledge, there 
has been no study reporting underweight as an independent predictor of MALE in patients 
with PAD. In our study, underweight was an independent predictor not only for MACE, but 
also for MALE. Furthermore, the predictive power of underweight (HR, 1.510) for MALE was 
comparable with other traditional predictors such as CLI (HR, 1.704) and end-stage renal 
disease (HR, 2.063).
The mechanism of adverse effects of underweight on clinical outcomes of PAD is not well 
established. A possible explanation is that low BMI is associated with unfavorable clinical 
factors such as old age, malnutrition, or sarcopenia.18-20) In our study, however, underweight 
remained a significant predictor for MACE and MALE even after adjustment for age and other 
covariates. Malnutrition, another plausible explanation for poor prognosis of underweight, is 
associated with sarcopenia, and causes loss of metabolic reserve. Malnutrition is frequently 
combined with inflammation in chronic diseases such as heart failure. Malnutrition, 
sarcopenia, and chronic inflammation aggravate one another, creating a vicious cycle of 
fragility, the so-called malnutrition-inflammation complex syndrome.21)
Sarcopenia is frequently combined with PAD, and its prevalence increases with decreasing 
BMI.22) In small single center study, sarcopenia has been shown to be associated with higher 
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death rate in patients with CLI (HR, 3.22; 95% CI, 1.24–9.11; p=0.02).23) The mechanism is 
not yet fully elucidated, however, aforementioned chronic inflammatory and protein wasting 
state of sarcopenia can be a plausible mechanism. Furthermore, level of adiponectin and 
carnitine, important anti-inflammory, anti-atherosclerotic, insulin sensitizing and pro-
myogenic hormone, was reduced in sarcopenia.24) It promotes metabolic dysfunction and 
atherosclerosis in sarcopenic patients, resulting in poor clinical prognosis. Recent national 
health data showed that preserved muscle mass plays a crucial role in better survival rate in 
same BMI category from underweight to obesity people.25) It suggested sarcopenia could be 
more precise prognostic factor than BMI.
It is uncertain whether underweight results from an advanced atherosclerotic process of 
PAD or other comorbidities. Generally, physicians tend to consider underweight patients as 
having better lipid profiles and less CVD than higher body weight patients. This presumption 
may lead to CVD not being diagnosed in its early stage, and to underweight patients being 
managed less aggressively. In addition, the relatively low blood pressure in the underweight 
patients and their more sensitive reaction to low doses of drugs can present additional 
hurdles in prescribing medications.
A previous study demonstrated that good nutritional status is an independent predictor 
of better clinical outcomes in patients undergoing EVT.26) However, there are currently no 
recommendations for underweight PAD patients to gain weight in order to improve clinical 
outcomes. Further studies are needed to elucidate the role of increasing muscle, nutritional 
support, and weight gain on prognosis of PAD in underweight patients.
Our study has some limitations. First, the present study is a retrospective analysis with 
potential selection and observational bias, and this type of study does not reveal cause-
and-effect relationships. Baseline characteristics and medical treatment showed significant 
difference between the different patient groups. There were more diabetes and hypertension 
in the overweight and obesity group than in the underweight and in the normal weight group. 
Accordingly, the overweight and the obesity group required more antiplatelet, lipid lowering, 
and antihypertensive medications than the underweight or the normal weight group. We 
tried to adjust the analysis outcomes based on the baseline characteristics. Second, the study 
population was confined to patients with PAD undergoing EVT. Thus, the results cannot be 
generalized to all patients with PAD. Third, BMI was estimated just once upon hospitalization 
for the index procedure. Therefore, the impact of changes in body weight on clinical 
outcomes during follow-up was not taken into account. Lastly, because the present registry 
database did not include information regarding nutrition, muscle mass, or physical activity, 
more detailed analysis of clinical factors leading to the underweight state was not feasible.
In conclusion, in patients with PAD undergoing endovascular therapy, underweight is an 
independent predictor for MACE and MALE, whereas overweight was associated with lower 
risk of MACE than normal weight.
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